Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy

  • Published : 2016.06.01
⟨ Previous Next ⟩

Abstract

Background: The limitations of total serum PSA values remain problematic, especially after an initial negative prostate biopsy. In this prospective study of Chilean men with a continued suspicion of prostate cancer due to a persistently elevated total serum PSA, abnormal digital rectal examination and initial negative prostate biopsy were compared with the use of the on-line Chun nomagram, detection of primary malignant circulating prostate cells (CPCs) and free percent PSA to predict a positive second prostate biopsy. We hypothesized that men negative for circulating prostate cells have a small risk of clinically significant prostate cancer and thus may be conservatively observed. Men positive for circulating prostate cells should undergo biopsy to confirm prostate cancer. Materials and Methods: Consecutive men with a continued suspicion of prostate cancer underwent 12 core TRUS prostate biopsy; age, total serum PSA and percentage free PSA and Chun nomagram scores were registered. Immediately before biopsy an 8ml blood simple was taken to detect primary mCPCs. Mononuclear cells were obtained by differential gel centrifugation and identified using double immunostaining with anti-PSA and anti-P504S. Biopsies were classifed as cancer/no-cancer, mCPC detecton test as negative/positive and the total number of cells/8ml registered. Areas under the curve (AUC) for percentage free PSA, Chun score and CPCs were calculated and compared. Diagnostic yields were calculated with reference to the number of possible biopsies that could be avoided and the number of clinically significant cancers that would be missed. Results: A total of 164 men underwent a second biopsy; 41 (25%) had cancer; the AUCs were 0.65 for free PSA, 0.76 for the Chun score and 0.87 for CPC detection, the last having a significantly superior prediction value (p=0.01). Using cut off values of free PSA <10%, Chun score >50% and ${\geq}1$ CPC detected, CPC detection had a higher diagnostic yield. Some 4/41 cancers complied with the criteria for active surveillance, free PSA and the Chun score missed a higher number of significant cancers when compared with CPC detection. Conclusions: Primary CPC detection outperformed the use of free PSA and the Chun nomagram in predicting clinically significant prostate cancer at repeat prostate biopsy.

Keywords

References

  1. Anastasiadis E, van der Meulen J, Emberton M (2014). Hospital admissions after TRUS biopsy of the prostate in men diagnoses with prostate cancer: A database analysis in England. Int J Urol, 22, 101-6.
  2. Beach R, Gown AM, Peralta-Venturina MN, et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol, 26, 1588-96. https://doi.org/10.1097/00000478-200212000-00006
  3. Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy, 1, 377-88 https://doi.org/10.1080/0032472031000141283
  4. Campbell MF, Wein AJ, Kavoussi LR (2011). Campbell's Urology 2011. V, Section II, chapter 3.
  5. Carlson GD, Calvanese CB, Partin AW (1998). An algorithm combining age, total PSA and percent free PSA to predict prostate cancer: results in 4298 cases. Urol, 52, 455-461 https://doi.org/10.1016/S0090-4295(98)00205-2
  6. Chun FK, Briganti A, Graefen M, et al (2007). Development and external validation of an extended repeat biopsy nomogram. J Urol, 177, 510-5. https://doi.org/10.1016/j.juro.2006.09.025
  7. Davis JW, Nakanishi H, Kumar VS, et al (2008). Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol, 179, 2187-91. https://doi.org/10.1016/j.juro.2008.01.102
  8. Djavan B, Zlotta A, Remzi M, et al (2000). Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol, 163, 1144-8. https://doi.org/10.1016/S0022-5347(05)67711-7
  9. Djavan B, Remzi M, Zlotta A, et al (2002). Novel artificial neural network for early detection of prostate cancer. J Clin Oncol, 20, 921-9. https://doi.org/10.1200/JCO.2002.20.4.921
  10. Eschwege P, Moutereau S, Droupy S, et al (2009). Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer, 100, 608-10. https://doi.org/10.1038/sj.bjc.6604912
  11. Eggener SE, Roehl KA, Catalona WJ (2005). Predictors of subsequent prostate cancer in men with a PSA of 2.6-4.0ng/ml and an initially negative prostate biopsy. J Urol, 174, 500-4. https://doi.org/10.1097/01.ju.0000165203.40973.0f
  12. Epstein JI, Walsh PC, Carmichael M, et al (1994), Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 271, 368-374. https://doi.org/10.1001/jama.1994.03510290050036
  13. Fizazi K, Morat L, Chauveinc L, et al (2007). High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol, 18, 518-21.
  14. Fowler JE Jr, Bigler SA, Miles D, et al (2000). Predictors of the first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol, 163, 813-8. https://doi.org/10.1016/S0022-5347(05)67810-X
  15. Graham J, Baker M, Macbeth F, et al (2008). Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ, 336, 610-2. https://doi.org/10.1136/bmj.39498.525706.AD
  16. Lopez E, Ohori M, Scardino PT, et al (2003). A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative seesion. J Urol, 170, 1184-88. https://doi.org/10.1097/01.ju.0000087451.64657.fa
  17. Moreno JG, Croce CM, Fischer R, et al (1992) Detection of hemato¬genous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2.
  18. Murray NP, Reyes E, Badinez L, et al (2013). Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications. J Oncol, 2013.
  19. Murray NP, Reyes E, Orellana N, et al (2013a). Cost benefit of the use of circulating prostate cells to detect prostate cancer. Arch Esp Urol, 66, 277-86.
  20. Murray NP, Reyes E, Orellana N, et al (2014). A comparative performance analysis of Total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men. Bio Med Research Int.
  21. Murray NP, Reyes E, Fuentealba C, et al (2014a). Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer. J Oncol.
  22. Panteleakou Z, Lembessis P. Sourla A, et al (2009). Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls andclinical relevance. Mol Med, 15, 101-14.
  23. Paterlini-Brechot P and Benali NL (2007). Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Letters, 253, 180-204. https://doi.org/10.1016/j.canlet.2006.12.014
  24. Pavlakis K, Stravodimos K, Kapetanakis T, et al (2010) Evaluation of routine applications of P504S, $34{\beta}E12$ and p63 immunostaining on 250 prostate needle biopsy specimens. Int Urol Nephrol, 42, 325-30. https://doi.org/10.1007/s11255-009-9622-1
  25. Raimondi C, Gradilone A, Naso G, et al (2011). Epithelialmesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat, 130, 449-55. https://doi.org/10.1007/s10549-011-1373-x
  26. Rodriguez LV, Terris Mk (1998). Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literatura. J Urol, 160, 2115-20. https://doi.org/10.1016/S0022-5347(01)62255-9
  27. Rubin MA, Zhou M, Dhanasekaran SM, et al (2001). alphamethylacyl Coenzyme-A racemase as a tissue biomarker for prostate cancer. JAMA, 287, 1662-70.
  28. Shariat SF, Karakiewicz PI, Roehrborn CG, et al (2008). An updated catalog of prostate cancer predictive tools. Cancer,